Sarepta Therapeutics (SRPT) Other Operating Expenses (2016 - 2026)

Sarepta Therapeutics' Other Operating Expenses history runs 11 years deep, the most recent figure standing at $109.5 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 20.78% year-over-year to $109.5 million in Q1 2026; TTM through Mar 2026 was $813.5 million, a 488.81% increase from a year earlier, with the FY2023 full-year figure at $102.0 million, changed N/A from the prior year.
• Other Operating Expenses fell to $109.5 million in Q1 2026 per SRPT's latest filing, from $399.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $399.4 million in Q4 2025 and bottomed at $31.6 million in Q1 2022.
• The 5-year median for Other Operating Expenses is $109.5 million (2026), against an average of $130.2 million.
• Across the five-year window, Other Operating Expenses soared 170.06% in 2025 and decreased 20.78% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at $31.6 million in 2022, then jumped by 222.57% to $102.0 million in 2023, then plunged by 49.84% to $51.2 million in 2024, then jumped by 680.66% to $399.4 million in 2025, then sank by 72.59% to $109.5 million in 2026.
• Per Business Quant, the three latest SRPT Other Operating Expenses figures stand at $109.5 million (Q1 2026), $399.4 million (Q4 2025), and $151.5 million (Q3 2025).